0.8492 USD
0 (-0.09%)
Taking everything into account, RMTI scores 2 out of 10 in our fundamental rating. RMTI was compared to 184 industry peers in the Health Care Equipment & Supplies industry. RMTI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. RMTI is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year RMTI has reported negative net income.
In the past year RMTI has reported a negative cash flow from operations.
RMTI had negative earnings in each of the past 5 years.
RMTI had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
With a decent Return On Assets value of -9.60%, RMTI is doing good in the industry, outperforming 61.50% of the companies in the same industry.
The Return On Equity of RMTI (-14.90%) is better than 63.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.6% | ||
| ROE | -14.9% | ||
| ROIC | N/A |
ROA(3y)-19.01%
ROA(5y)-32.81%
ROE(3y)-57.83%
ROE(5y)-310.02%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
RMTI has a Gross Margin of 15.81%. This is amonst the worse of the industry: RMTI underperforms 81.82% of its industry peers.
In the last couple of years the Gross Margin of RMTI has grown nicely.
The Profit Margin and Operating Margin are not available for RMTI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 15.81% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y30.04%
2. Health
2.1 Basic Checks
RMTI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RMTI has more shares outstanding
Compared to 5 years ago, RMTI has more shares outstanding
The debt/assets ratio for RMTI has been reduced compared to a year ago.
2.2 Solvency
RMTI has an Altman-Z score of -7.17. This is a bad value and indicates that RMTI is not financially healthy and even has some risk of bankruptcy.
RMTI has a worse Altman-Z score (-7.17) than 75.40% of its industry peers.
A Debt/Equity ratio of 0.26 indicates that RMTI is not too dependend on debt financing.
RMTI has a Debt to Equity ratio (0.26) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -7.17 |
ROIC/WACCN/A
WACC8.23%
2.3 Liquidity
RMTI has a Current Ratio of 3.92. This indicates that RMTI is financially healthy and has no problem in meeting its short term obligations.
RMTI has a Current ratio of 3.92. This is in the better half of the industry: RMTI outperforms 66.84% of its industry peers.
A Quick Ratio of 3.50 indicates that RMTI has no problem at all paying its short term obligations.
RMTI has a better Quick ratio (3.50) than 68.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.92 | ||
| Quick Ratio | 3.5 |
3. Growth
3.1 Past
The earnings per share for RMTI have decreased strongly by -213.73% in the last year.
RMTI shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -23.60%.
RMTI shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.61% yearly.
EPS 1Y (TTM)-213.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-200%
Revenue 1Y (TTM)-23.6%
Revenue growth 3Y17.9%
Revenue growth 5Y10.61%
Sales Q2Q%-43.75%
3.2 Future
Based on estimates for the next years, RMTI will show a very negative growth in Earnings Per Share. The EPS will decrease by -74.82% on average per year.
Based on estimates for the next years, RMTI will show a decrease in Revenue. The Revenue will decrease by -9.82% on average per year.
EPS Next Y-750%
EPS Next 2Y-131.15%
EPS Next 3Y-74.82%
EPS Next 5YN/A
Revenue Next Year-32.86%
Revenue Next 2Y-14.8%
Revenue Next 3Y-9.82%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
RMTI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RMTI. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
RMTI's earnings are expected to decrease with -74.82% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-131.15%
EPS Next 3Y-74.82%
5. Dividend
5.1 Amount
RMTI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:RMTI (12/19/2025, 8:14:21 PM)
0.8492
0 (-0.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners8.57%
Inst Owner Change-43.45%
Ins Owners4.2%
Ins Owner Change-0.11%
Market Cap33.47M
Revenue(TTM)75.58M
Net Income(TTM)-5.52M
Analysts82.5
Price Target3.83 (351.01%)
Short Float %2.6%
Short Ratio2.3
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.49%
Min EPS beat(2)-8.93%
Max EPS beat(2)1.96%
EPS beat(4)2
Avg EPS beat(4)-45.86%
Min EPS beat(4)-198.04%
Max EPS beat(4)21.57%
EPS beat(8)5
Avg EPS beat(8)39.36%
EPS beat(12)8
Avg EPS beat(12)32.73%
EPS beat(16)12
Avg EPS beat(16)34.5%
Revenue beat(2)0
Avg Revenue beat(2)-3.69%
Min Revenue beat(2)-3.86%
Max Revenue beat(2)-3.53%
Revenue beat(4)2
Avg Revenue beat(4)0.26%
Min Revenue beat(4)-3.86%
Max Revenue beat(4)6.2%
Revenue beat(8)5
Avg Revenue beat(8)1.8%
Revenue beat(12)8
Avg Revenue beat(12)2.62%
Revenue beat(16)9
Avg Revenue beat(16)0.27%
PT rev (1m)0%
PT rev (3m)-6.25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)11.11%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.49%
Revenue NY rev (1m)-1.33%
Revenue NY rev (3m)-1.33%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.44 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.9 | ||
| P/tB | 1.27 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.16
EYN/A
EPS(NY)-0.11
Fwd EYN/A
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS1.92
BVpS0.94
TBVpS0.67
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.6% | ||
| ROE | -14.9% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 15.81% | ||
| FCFM | N/A |
ROA(3y)-19.01%
ROA(5y)-32.81%
ROE(3y)-57.83%
ROE(5y)-310.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y30.04%
F-Score3
Asset Turnover1.31
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 38.88% | ||
| Cap/Sales | 1.13% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.92 | ||
| Quick Ratio | 3.5 | ||
| Altman-Z | -7.17 |
F-Score3
WACC8.23%
ROIC/WACCN/A
Cap/Depr(3y)323.45%
Cap/Depr(5y)234.89%
Cap/Sales(3y)5.5%
Cap/Sales(5y)3.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-213.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-200%
EPS Next Y-750%
EPS Next 2Y-131.15%
EPS Next 3Y-74.82%
EPS Next 5YN/A
Revenue 1Y (TTM)-23.6%
Revenue growth 3Y17.9%
Revenue growth 5Y10.61%
Sales Q2Q%-43.75%
Revenue Next Year-32.86%
Revenue Next 2Y-14.8%
Revenue Next 3Y-9.82%
Revenue Next 5YN/A
EBIT growth 1Y-843.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-125.54%
EBIT Next 3Y-26.07%
EBIT Next 5YN/A
FCF growth 1Y87.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y79.06%
OCF growth 3YN/A
OCF growth 5YN/A
ROCKWELL MEDICAL INC / RMTI FAQ
What is the ChartMill fundamental rating of ROCKWELL MEDICAL INC (RMTI) stock?
ChartMill assigns a fundamental rating of 2 / 10 to RMTI.
What is the valuation status for RMTI stock?
ChartMill assigns a valuation rating of 0 / 10 to ROCKWELL MEDICAL INC (RMTI). This can be considered as Overvalued.
How profitable is ROCKWELL MEDICAL INC (RMTI) stock?
ROCKWELL MEDICAL INC (RMTI) has a profitability rating of 2 / 10.
Can you provide the expected EPS growth for RMTI stock?
The Earnings per Share (EPS) of ROCKWELL MEDICAL INC (RMTI) is expected to decline by -750% in the next year.